Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $23.2300 (-2.8%) ($22.7300 - $23.9500) on Mon. Apr. 2, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.38% (three month average) | RSI | 19 | Latest Price | $23.2300(-2.8%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -6.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) QQQ(18%) XOP(18%) ARKK(17%) | Factors Impacting ADMS price | ADMS will decline at least -2.19% in a week (0% probabilities). VIXM(-11%) UNG(-10%) BNDX(-9%) UUP(-7%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.19% (StdDev 4.38%) | Hourly BBV | 0 () | Intraday Trend | -2.7% | | | |
|
1 - 5 Day Possible Target | $13.4(-42.32%) | Resistance Level | $25.51 | 5 Day Moving Average | $23.79(-2.35%) | 10 Day Moving Average | $24.46(-5.03%) | 20 Day Moving Average | $25.51(-8.94%) | To recent high | -45.5% | To recent low | 0% | Market Cap | $657m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |